Breaking News
May 24, 2018 - Robust Immune Responses for Herpes Zoster Subunit Vaccine
May 24, 2018 - Optical Coherence Tomography | Texas Heart Institute
May 24, 2018 - Type 2 diabetes slowly rising in Auckland kids – Pacific and Māori have highest rates
May 24, 2018 - Study explores brain chemistry of alcohol exposure in people with family history of AUD
May 24, 2018 - Study shows AVATS procedure as safe, effective alternative for patients deemed ‘inoperable’
May 24, 2018 - Comparative Analysis of a Complex Monoclonal Antibody
May 24, 2018 - Penn investigators discover source of immune molecule involved in nasal polyps, asthma
May 24, 2018 - Berries and Grapes May Keep You Breathin’ Easy
May 24, 2018 - Access and utilization of dental services for Medicaid children 2013-2015
May 23, 2018 - New research raises concern about rate of postpartum hemorrhage
May 23, 2018 - Researchers create new modeling framework that takes a zoonotic perspective on Ebola
May 23, 2018 - Study compares bacteria in humans to the laboratory
May 23, 2018 - Frequent sauna bathing reduces risk of stroke
May 23, 2018 - Landmark trial to test implantable defibrillator in diabetic patients with history of heart attack
May 23, 2018 - Vitamin C consumption may reduce harm to baby’s lungs due to smoking during pregnancy
May 23, 2018 - Researchers complete genomic map of chronic lymphocytic leukemia
May 23, 2018 - Medical students take to the streets to learn about real world problems at the root of poor health
May 23, 2018 - New efforts to curb high blood pressure in Asia
May 23, 2018 - Malaria-causing parasite seeks refuge inside the liver to replicate and survive
May 23, 2018 - Slower rates of stimulation may be more effective in brain therapy, suggests research
May 23, 2018 - Study finds connection between one partner’s BMI and other spouse’s risk of developing diabetes
May 23, 2018 - Mapping the Genes Responsible for Pluripotency
May 23, 2018 - FDA Alert: Homeopathic Teething Drops, Nausea Drops, Intestinal Colic Drops, Stomach Calm, Expectorant Cough Syrup, Silver-Zinc Throat Spray, and Argentum Elixir by MBI Distributing: Recall
May 23, 2018 - Genetic fixer-uppers may predict bladder cancer prognosis
May 23, 2018 - Investigational technology could increase donor organ supply for lung transplants
May 23, 2018 - Prediabetic patients with OSA could lower their resting heart rates by using CPAP
May 23, 2018 - Schizophrenics’ blood samples feature genetic material from more types of microorganisms
May 23, 2018 - Subtle hearing deficits can change the brains of young people
May 23, 2018 - New study shows increased rates of hospitalization for suicide among youths
May 23, 2018 - Proportion of Drug-Intoxicated Organ Donors on the Rise in U.S.
May 23, 2018 - Using virtual biopsies to improve melanoma detection
May 23, 2018 - Compassion meditation training may increase brain’s resilience to suffering of other people
May 23, 2018 - New AAD PSA uses social media imagery to highlight tanning hazards
May 23, 2018 - Frequent MRSA surveillance could contain infection in newborns, study finds
May 23, 2018 - Medicaid expansion linked to reduction in ICU utilization
May 23, 2018 - Proteins moderating nicotine dependence may help fat cells burn energy
May 23, 2018 - Researchers identify mechanisms that regulate mammary gland development
May 23, 2018 - ‘Low-Alcohol’ Booze Labels May Backfire
May 23, 2018 - Social isolation could increase risk of death, hospitalizations for heart failure patients
May 23, 2018 - New research shows that children with autism are able to create imaginary friends
May 23, 2018 - New technology could make prosthetic use more intuitive and reliable
May 23, 2018 - HU researchers explore how simulated microgravity affects gene expression, muscle cell differentiation
May 23, 2018 - Researchers develop injectable bandage to stop fatal blood loss, activate wound healing
May 23, 2018 - Exercising for 4-5 days per week is needed to keep the heart young
May 23, 2018 - Porvair Sciences offers wide range of reagent reservoirs for use with automated liquid handling systems
May 23, 2018 - New study unravels secrets of HIV’s persistence
May 23, 2018 - IDF launches initiative to improve health services for displaced people with diabetes
May 23, 2018 - Maintaining healthy weight between early adulthood and middle age could help avoid diabetes
May 23, 2018 - DNA vaccine shows promise for colorectal cancer
May 23, 2018 - Abnormal brain connections seen in preschoolers with autism
May 23, 2018 - Study finds increase in number of calls to US Poison Control Centers about ADHD medication exposures
May 23, 2018 - Yoghurt before a meal packed with health benefits
May 23, 2018 - New tool predicts the lifetime risk of Alzheimer’s
May 23, 2018 - Scientists reveal mechanisms that may help preterm infants extend nephron development window
May 23, 2018 - Unnecessary antibiotic use for asthma exacerbations linked to increased hospital stays, costs
May 23, 2018 - Quitting cigarettes linked to better lung health than long-term light smoking
May 23, 2018 - Researchers shed light on how androgen deprivation therapy increases risk for cardiovascular mortality
May 23, 2018 - Ingesting blue dye tablet during colonoscopy aids in detecting difficult-to-see polyps
May 23, 2018 - Patients with low-back pain benefit from early physical therapy
May 23, 2018 - Researchers discover link between tuberculosis and Parkinson’s disease
May 23, 2018 - FDA Approves Doptelet (avatrombopag) for Chronic Liver Disease Patients with Thrombocytopenia who are Undergoing a Medical Procedure
May 23, 2018 - Is knee pain linked to depression?
May 23, 2018 - Research team uncovers new information that more accurately explains formation of tumors
May 23, 2018 - Brain stimulation shows promise in treating obesity by reducing food cravings
May 23, 2018 - Mediterranean diet may protect people from negative effects of air pollution
May 23, 2018 - Researcher aims to develop virtual biopsy tool for early melanoma detection
May 23, 2018 - Medical centers more willing to perform lung transplants for severe alcoholic hepatitis patients
May 23, 2018 - The brain may tune to social learning even at rest, finds study
May 23, 2018 - Eczema drug alleviates asthma symptoms and improves lung function
May 23, 2018 - Researchers to test two-pronged approach in humans to treat advanced colorectal cancer
May 23, 2018 - FDA Alert: Juluca, Tivicay, Triumeq (dolutegravir): FDA to Evaluate
May 23, 2018 - Neuroscientists say daily ibuprofen can prevent Alzheimer’s disease
May 23, 2018 - Scientists decipher workings of little-understood bacterial riboswitch
May 23, 2018 - Investigational drug offers hope of relief for celiac disease patients exposed to gluten
May 23, 2018 - PCI along with prescribed drugs better than medication alone for treating for people with heart disease
May 23, 2018 - ToolGen’s CRISPR/Cas9 gene editing platform improves T-cell anti-tumor activity in mouse model
May 22, 2018 - FDA approves new drug to treat thrombocytopenia in adults with chronic liver disease
May 22, 2018 - CSIRO study urges Australians to avoid junk protein foods for healthy weight loss
May 22, 2018 - Breath Test Shows Promise for Diagnosis of Esophagogastric CA
May 22, 2018 - Common class of drugs linked to dementia even when taken 20 years before diagnosis
Mixed Results with Regimens for Older AML Patients

Mixed Results with Regimens for Older AML Patients

image_pdfDownload PDFimage_print

ATLANTA — A dual oral regimen for older patients with untreated acute myeloid leukemia (AML) failed to improve survival as compared with a single drug in a randomized trial reported here.

The combination of sapacitabine and decitabine led to a median overall survival of 5.9 months in patients ≥70 versus 5.7 months with decitabine alone. Results were similar for all secondary endpoints, as well.

A subgroup analysis suggested the combination might have greater activity in patients with a baseline white blood-cell count (WBC) <10,000, Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center in Houston, reported here at the American Society of Hematology meeting.

“The stratified subgroup analyses suggested that in older patients without aggressive disease the addition of sapacitabine might potentially improve the outcome, with a chance for better median survival and a higher complete response rate,” Kantarjian said. “We think this hypothesis is plausible and reflects the heterogeneity of AML, where patients with more aggressive disease need more intensive therapy but for patients with lower-risk, less aggressive disease, the addition of sapacitabine could improve the outcome.”

“Sapacitabine is an oral agent, making it more convenient, and it could be administered as outpatient therapy. The statistical robustness of the subgroup results is currently being investigated.”

With almost 500 patients, the negative randomized trial was by far the largest of several studies evaluating regimens for older patients with AML. Collectively, the results were mixed:

  • Long-term follow-up for a phase I/II dose-escalation study of venetoclax (Venclexta) and low-dose cytarabine showed a median overall survival of 11.4 months in 61 patients.
  • A phase II study of fixed-dose liposomal cytarabine/daunorubicin (CPX-351, Vyxeos) produced complete responses in 20% to 53% of patients in different dose groups.
  • Maintenance therapy with the anti-KIR antibody lirilumab failed to improve survival in older AML patients in complete remission.

Sapacitabine/Decitabine

In preliminary trials, sapacitabine demonstrated single-agent activity in AML and myelodysplastic syndromes. The agent exhibited a safety profile suitable for long-term administration, said Kantarjian. An evaluation of the sapacitabine-decitabine combination in older patients with AML led to complete responses in 24% and a median survival of 7.7 months.

The multicenter randomized, open-label trial of the combination included 482 patients who were either not candidates for or had refused intensive therapy. They were randomized to decitabine alone or to the combination, administered in alternating 8-week cycles. The primary endpoint was overall survival, analyzed after 444 deaths.

The study population had a median age of 77 to 78, and more than 90% of patients qualified for the trial because their physicians recommended low-intensity treatment.

In addition to the lack of difference in overall survival, the two randomized groups had similar rates of complete response (17% for the combination, 11% for decitabine alone), 1-year survival (34%, 35%), number of transfusions of red blood cells and platelets per week (1.2, 1.1), median number of hospital days (15, 14), percentage of days alive out off hospital during the first year after randomization (88%, 84%).

The subgroup analysis showed that patients with WBC <10,000 (66% of the study population) had a median survival of 8.0 months with the combination versus 5.8 months with decitabine alone, which represented a trend toward improvement (HR 0.84, 95% CI 0.66 to 1.06, P=0.1446). Rates of complete response in the subgroup were 21% with the combination and 8.6% with decitabine alone (P=0.0017), and the combination achieved durable responses, Kantarjian said.

Additional Studies

The rationale for the venetoclax trial came from the recognition that older patients with AML often receive only palliative treatment, said Andrew Wei, MD, of Monash University in Melbourne, Australia. Low-dose cytarabine is often used in patients who cannot tolerate intensive treatment, but the drug produces objective responses in fewer than 20% of patients.

Wei and colleagues previously reported a complete response rate >60% for the combination of venetoclax and low-dose cytarabine in older AML patients (median age 74) ineligible for intensive therapy. He updated the findings with a survival analysis, performed after all patients had been followed for more than a year.

The patients had a 1-year overall survival of 45.9%. The combination led to complete responses in 38 of 61 patients, and the median duration of complete response was 13.2 months. Among patients who achieved complete response, the median survival had yet to be reached, but was at least 16.9 months. Complete response was associated with a 12-month overall survival of 100%.

The results provided the basis for an ongoing phase III pivotal trial, said Wei.

The trial of liposomal cytarabine-daunorubicin involved 55 patients treated with one of three doses of the combination (1.0 mg cytarabine/0.44 mg daunorubicin per unit). All patients had a high risk of induction mortality, defined as age ≥60 plus one additional risk factor or age <60 and two clinical risk factors. CPX-351 led to complete responses in three of 15 (20%) patients treated at the lowest dose, 10 of 24 (42%) treated with the intermediate dose, and eight of 15 (53%) patients treated with the highest dose, reported Gautam Borthakur, MD, of MD Anderson Cancer Center.

Median overall survival was 3.6 months with the lowest dose of CPX-351 (50 U/m2), 8.2 months at the intermediate dose (75 U/m2), and 6.1 months at the highest dose (100 U/m2). Relapse-free survival ranged between 3.0 and 5.8 months, with the best results occurring in patients who received the intermediate dose.

The results added to previously favorable findings from studies of CPX-351, including a large randomized trial of older patients with untreated AML. In the randomized trial, CPX-351 demonstrated superiority versus a standard 3 + 7 regimen with respect to complete response, overall survival, and event-free survival.

The monoclonal antibody lirilumab is a checkpoint inhibitor targets killer immunoglobulin-like receptors (KIRs). The drug blocks the NK cell inhibitor receptor and prevents interaction with HLA-C class I molecules and potentiate NK cell killing, said Norbert Vey, MD, of Paoli-Calmettes Institute, in Marseilles, France.

Two different doses of lirilumab were evaluated as maintenance therapy in a randomized, placebo-controlled, phase II trial involving 153 patients (median age 70) with AML in complete response. The primary endpoint was leukemia-free survival. Neither dose of the antibody improved survival compared with placebo (13.9 months versus 17.6 months with low-dose lirilumab and 6.7 months with the higher dose).

The sapacitabine study was supported by Cyclacel.

Kantarjian disclosed relationships with Pfizer, ARIAD, Bristol-Meyers Squibb, Novartis, Delta-Fly Pharma, and Amgen.

The study of venetoclax and cytarabine was supported by AbbVie.

Wei disclosed relationships with AbbVie, Celgene, Novartis, Amgen, and Servier.

Borthakur reported no relevant relationships with industry. Co-investigators disclosed multiple relationships with industry, including Jazz Pharmaceuticals, which manufactures CPX-351.

The lirilumab study was supported by Bristol-Myers Squibb.

Vey disclosed relationships with Bristol-Myers Squibb and Innate Pharma.

1969-12-31T19:00:00-0500

last updated

Tagged with:

About author

Related Articles